Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Gut microbiome shifts may begin before Alzheimer’s symptoms appear

3

Aug 2026

Gut microbiome shifts may begin before Alzheimer’s symptoms appear

A narrative review links reduced SCFA-producing gut bacteria and altered microbial metabolism with Alzheimer’s disease, while early evidence suggests similar changes may appear before cognitive symptoms. Mediterranean, DASH, MIND, and prudent diets are associated with beneficial microbial profiles, but direct evidence connecting diet, the microbiome, and amyloid pathology remains limited.

Children remain more vulnerable to influenza despite protective antibody levels

3

Aug 2026

Children remain more vulnerable to influenza despite protective antibody levels

Researchers analyzing 1,518 South African household participants found that higher pre-season antibody titers were associated with lower infection risk for three of four influenza viruses studied. Children remained more susceptible after accounting for measured exposure and antibody titers, while younger children shed viral RNA longer than older adults.

A 10-country survey finds an unexpected air pollution awareness gap

2

Aug 2026

A 10-country survey finds an unexpected air pollution awareness gap

Researchers surveyed 10,618 adults across 1,372 localities in the world’s 10 most populous countries and matched their responses with average 2019-2021 PM2.5 concentrations. Higher PM2.5 exposure was associated with lower air-quality knowledge but greater concern and more frequent protective behaviors, with patterns differing across demographic groups.

Daily tomatoes lowered a key marker of liver fat in MASLD trial

2

Aug 2026

Daily tomatoes lowered a key marker of liver fat in MASLD trial

An exploratory randomized trial found that 200 g of raw tomatoes plus 50 g of tomato sauce daily for six weeks produced a greater reduction in CAP-defined hepatic steatosis than a tomato-free diet in adults with MASLD. The improvement occurred without major weight or metabolic changes, but larger and longer trials are needed to confirm its clinical significance.

Daytime cortisol patterns track cognitive decline but not Alzheimer’s disease risk

2

Aug 2026

Daytime cortisol patterns track cognitive decline but not Alzheimer’s disease risk

In 3,895 older adults, moderate daytime cortisol variability was associated with better cognition and slower decline, while the highest daily cortisol exposure was linked to poorer cognition and faster decline. Cortisol patterns differed between Black and White participants, but their relationships with cognition were similar, and none predicted incident Alzheimer’s disease.

Study links higher body fat to lower sperm counts despite normal BMI

2

Aug 2026

Study links higher body fat to lower sperm counts despite normal BMI

Among 1,058 Danish men, higher body fat percentage was associated with lower total sperm count and altered reproductive hormone levels, but not testicular volume. Body fat percentage showed stronger links with several semen measures than BMI or waist-to-height ratio, with the sperm-count association strengthening among men with normal BMI.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.